Vir Biotechnology, Inc. (VIR)
11.70
+0.58
(+5.22%)
USD |
NASDAQ |
Oct 09, 16:00
11.70
0.00 (0.00%)
After-Hours: 20:00
Vir Biotechnology Cash from Operations (Quarterly) : 123.33M for June 30, 2026
Cash from Operations (Quarterly) Chart
Historical Cash from Operations (Quarterly) Data
| Date | Value |
|---|---|
| June 30, 2026 | 123.33M |
| March 31, 2026 | -132.39M |
| December 31, 2025 | -25.88M |
| September 30, 2025 | -167.57M |
| June 30, 2025 | -120.22M |
| March 31, 2025 | -78.12M |
| December 31, 2024 | -87.64M |
| September 30, 2024 | -171.48M |
| June 30, 2024 | -77.85M |
| March 31, 2024 | -109.39M |
| December 31, 2023 | -107.93M |
| September 30, 2023 | -155.83M |
| June 30, 2023 | -389.25M |
| March 31, 2023 | -125.78M |
| December 31, 2022 | 35.13M |
| September 30, 2022 | 117.90M |
| Date | Value |
|---|---|
| June 30, 2022 | 960.14M |
| March 31, 2022 | 550.09M |
| December 31, 2021 | 7.695M |
| September 30, 2021 | -105.81M |
| June 30, 2021 | 140.06M |
| March 31, 2021 | -89.53M |
| December 31, 2020 | -82.05M |
| September 30, 2020 | -49.84M |
| June 30, 2020 | -10.64M |
| March 31, 2020 | -48.41M |
| December 31, 2019 | -38.88M |
| September 30, 2019 | |
| June 30, 2019 | |
| March 31, 2019 | |
| December 31, 2018 | -29.51M |
Cash From Operations Definition
Represents the net cash flow from the company's business operations.
Cash from Operations (Quarterly) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Cash from Operations (Quarterly) Benchmarks
| Moderna, Inc. | -526.00M |
| Vaxcyte, Inc. | -232.47M |
| Caribou Biosciences, Inc. | -22.79M |
| Arrowhead Pharmaceuticals, Inc. | -177.47M |
| Oncolytics Biotech, Inc. | -8.066M |
Cash from Operations (Quarterly) Related Metrics
| Cash from Investing (Quarterly) | -197.14M |
| Cash from Financing (Quarterly) | 78.38M |
| Free Cash Flow | -203.59M |
| Free Cash Flow Per Share (Quarterly) | 0.7301 |
| Free Cash Flow to Equity (Quarterly) | 125.60M |
| Free Cash Flow to Firm (Quarterly) | 123.29M |
| Free Cash Flow Yield | -11.71% |